We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Giant Cell Arteritis and Anakinra Trial (GiAnT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02902731
Recruitment Status : Unknown
Verified February 2020 by University Hospital, Caen.
Recruitment status was:  Recruiting
First Posted : September 16, 2016
Last Update Posted : February 25, 2020
Hôpital Claude-Huriez
Amiens University Hospital
University Hospital, Rouen
University Hospital, Limoges
Central Hospital Saint Quentin
Valenciennes Hospital, Valenciennes, FRANCE
Information provided by (Responsible Party):
University Hospital, Caen

Brief Summary:

SYNOPSIS The giant cell arteritis (GCA) is the most frequent vasculitis in people over 50 years. Despite recent progress and physiopathogenic, corticosteroids remains the standard treatment for decades with a very good initial clinical efficacy but a high relapse rate (nearly 40% to 6,5 months) during its decay. This sensible population is particularly exposed to the side effects of corticosteroids, leading to think about savings strategies. But the association of immunosuppressive therapy and/or anti- TNFα has not demonstrated benefits in terms of efficiency or long-term tolerance to cumulative doses of prednisone. The responsibility of proinflammatory cytokines such as TNFα, IL- 6 and IL-1 has been studied in the pathogenesis of GCA in temporal artery walls and in mouse models. The primary pathogenic role of IL- 1 is based on the increase in serum or nuclear protein itself or that of its mRNA. The study of temporal artery biopsies has shown increased local production of IL- 1β mRNA, IL- 6 and TGFβ (indicative of macrophage activation ) and those of INFɣ and IL 2 (indicative of T lymphocyte activation). Recently, Ly et al (Ly KH JBS 2014) reported the efficacy of anakinra, a recombinant molecule of IL- 1RA specifically blocking the IL- 1 α/β, in three cases GCA refractory to conventional treatments.

Here investigators propose a randomized, multicenter, controlled, double-blind study of anakinra against placebo in addition to corticosteroids in the treatment of GCA.

This study will include 70 patients randomized equally in both arms: reference treatment (prednisone plus placebo) or the experimental treatment (prednisone + anakinra). Treatment with prednisone will be identical in the two arms, namely a dose of 0.7 mg/kg/day orally on day 1, followed by a progressive decrease in the dose pattern depending on the weight. In the experimental arm, dose of anakinra is the one usually used, ie 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (S16). In the reference arm of the treatment, a placebo anakinra is associated with corticosteroid in the same packaging, duration and respecting the double-blind.

Investigators thus hypothesized that the addition of anakinra to corticosteroid compared to placebo added to the latter, will show a significant decrease in GAC relapse rate. Indeed, the challenge of corticosteroid therapy in this disease is not so much a problem of initial effectiveness, than the adverse events related to relapses and steroid dependence.

Condition or disease Intervention/treatment Phase
Giant Cell Arteritis Drug: PLACEBO Drug: ANAKINRA Phase 3

Detailed Description:

Side assumptions investigators made are that the patients receiving anakinra in add-on therapy will have: a time and a complete remission rate respectively shorter and higher, fewer relapses and a decrease of the total consumption of prednisone over a 12- month follow-up.

This controlled study is the first to assess the inhibition of the IL- 1 pathway in the GCA with anakinra in add-on therapy with corticosteroids in patients newly diagnosed or on relapse. The purpose of this work is to support the following proof of concept of the addition of anakinra to corticosteroid therapy in the treatment of GCA: potential synergies of this association and intrinsic therapeutic action of anakinra in patient newly diagnosed, and this without loss of opportunity for patients that will benefit all of the reference treatment. The other originality of this study is to demonstrate the steroid-sparing effect of targeting interleukin -1, which is per se a therapeutic and nosologic innovation for this disease. Finally, ancillary biological studies will clarify the mode of action of the anti-cytokine therapy and identify markers of response to this biotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Controlled, Double-blind Study of Anakinra Against Placebo in Addition to Steroids in Giant Cell Arteritis
Actual Study Start Date : May 11, 2017
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Anakinra

Arm Intervention/treatment
Placebo Comparator: placebo
PLACEBO + Usual use of tapering doses of oral prednisone
subcutaneous injection of placebo every day during 16 weeks
Other Name: comparative drug

Experimental: anakinra

ANAKINRA : dose of anakinra is 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (W16). The dose of Anakinra will be adapted to that recommand according to renal function.

Intervention Anakinra in add on Therapy.

subcutaneous injection of anakinra every day during 16 weeks

Primary Outcome Measures :
  1. global relapse rate [ Time Frame: Week 26 ]

Secondary Outcome Measures :
  1. specific relapse rate [ Time Frame: Week 4 to Week 16 ]
  2. specific relapse rate [ Time Frame: Week 17 to Week 26 ]
  3. specific relapse rate [ Time Frame: W27 to W52 ]
  4. speed efficiency : time of obtaining a complete remission over a follow up of 52 weeks period [ Time Frame: baseline up to 52 weeks ]
  5. number of first relapse [ Time Frame: baseline up to 52 weeks ]
  6. cumulative and the average dose of prednisone used [ Time Frame: baseline up to 52 weeks ]
  7. Safety according CTCAE v4.0 [ Time Frame: baseline up to 52 weeks ]

Other Outcome Measures:
  1. T-cells (Th1, Th2, Th17 et Treg) et T CD8 (Tc1, Tc2, Tc17) [ Time Frame: at Week 0, Week 16 ]
  2. Cytokines (IL-6, IL-17, IFN-γ, IL-1β et TNF-α) [ Time Frame: at Week 0, Week 16 ]
    1. T-cells (Th1, Th2, Th17 et Treg) et T CD8 (Tc1, Tc2, Tc17)
    2. Cytokines (IL-6, IL-17, IFN-γ, IL-1β et TNF-α)
    3. vascular smooth muscles, fibroblastes (cytokines, inflammasome)

  3. vascular smooth muscles, fibroblastes (cytokines, inflammasome) [ Time Frame: at Week 0, Week 16 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   51 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Minimum Age: 51 Years

Maximum Age:

Gender: Both Accepts Healthy Volunteers?: No


Inclusion Criteria: (Giant cell arteritis = GCA)

Age ≥ 50 years

Patient with temporal arteritis giant cell match 3 of the 5 criteria of the American College of Rheumatology (ACR) that:

Given a temporal artery biopsy compatible with a diagnosis of GCA (not necrotizing arteritis, giant cell with a granulomatous inflammatory infiltrate, usually localized to the intima-media junction, makes lymphocytes, macrophages and multinucleated giant cells; or minimum detection of a chronic inflammatory infiltrate fact lymphocytes and some neutrophils or eosinophils without giant cells).

Either abdominal thoracic aortitis diagnosed by:

  • Angio CT: circumferential thickening of the aortic wall more than 3 mm, in the absence of adjacent plaque and active infection.
  • MR angiography: wall thickening of the aortic wall with hyperintense on T1 weighted and T2 weighted enhancement after gadolinium injection.
  • PET scanner: increased uptake of FDG by the aorta and its branches is not typical for GCA and may be in the atheroma. The PET scanner is probably a very sensitive technique but not specific enough to retain the diagnosis of GCA. We therefore consider the PET CT as a diagnostic method of secondary aortite the GCA if there simultaneously on the same exam fixing aortic (thoracic or abdominal) and blood of large caliber (artery (s) axillary ( s), subclavian (s) and / or carotid (s) of FDG.

Newly diagnosed disease and from corticosteroid started up to 14 days, the initial dose is less or equal to1 mg / Kg or

GCA recurrence of continuous therapy with corticosteroids (including hydroprednisone) and / or immunosuppression was stopped for at least 6 months. At the time of recurrence, at least 3 of 5 ACR criteria for the diagnosis of GCA must be present. Furthermore :

  • if BAT (Biopsy of the temporal artery) was positive at the time of initial diagnosis, it is not necessary to make a new.
  • if BAT was negative, the patient can not be included after completion of a new BAT which will be positive or if there is a aortite, evidenced by angio-CT or MR angiography or PET scanner.

For men and women of childbearing age, effective contraception must be used in the patient or his partner for the duration of treatment with anakinra (or placebo) and for 3 months after treatment. Also, breastfeeding is allowed after 3 months of stopping anakinra. Women considered not at risk of pregnancy are defined with menopause for at least a year or surgically sterile (tubal ligation, bilateral oophorectomy or hysterectomy)

Patient wo has given its written consent Patient affiliated with a social security

Exclusion Criteria:

Subjects checking one of the criteria for non-inclusion may be eligible to participate in the research. These criteria may include:

  1. pathologies, habitus or other patient characteristics

    • Pregnancy, breastfeeding women or women of childbearing potential not using contraception
    • dementia syndrome
    • Patient not observing
    • Patients who live more than 150 km from the investigation center
    • ethyl or drug intoxication history that required hospitalization in the previous year
    • Patient monitoring and / or treated to another autoimmune disease or known inflammatory
    • Hypersensitivity to anakinra or any of its excipients (Sodium citrate (E331), sodium chloride, disodium edetate (E385), polysorbate 80 (E433), sodium hydroxide (E524), water for injections, substrates of origin: Escherichia coli proteins)
    • Person under judicial protection, guardianship
    • Person deprived of liberty
    • Person not beneficiaries of the social security system
  2. Other therapeutic

    - Patient has already started (or stopped there less than 6 months) in a protocol or not frame to its ACG or another disease, treatment with anti TNF-alpha, methotrexate, cyclosporine, cyclophosphamide, dapsone or bolus corticosteroids.

    • Patients on long-term glucocorticoid for another condition
    • Early treatment of CAG disease with a dose> 1 mg / kg whatever the duration
    • Immunization with live vaccines / mitigated during the 8 weeks
  3. Infectious diseases

    • Chronic viral hepatitis (acute or) B or C
    • HIV Infection
    • Persistent infection or severe infection requiring hospitalization or treatment with IV antibiotics during the 30 days prior to inclusion
    • Infection requiring an oral antibiotic treatment in the preceding 14 days inclusion
    • History of active tuberculosis, histoplasmosis or listeriosis
    • latent TB Signs (based on a history of untreated contagion, an opacity of greater than 1 cm in diameter on chest x-ray, or an in vitro test (Quantiferon Gold or T-Spot TB) positive. A history of tuberculosis disease or latent TB whose treatment is completed and has been properly conducted is not an exclusion criterion, whatever the result of Quantiferon or T-Spot TB.
  4. Unstable disease

    • Uncontrolled diabetes with a history of recurrent infections
    • unstable ischemic heart
    • Heart failure ≥ stage III / IV NYHA
    • Stroke recent (<6 months)
    • Or any other severe disease resulting in the opinion of the investigator, a risk to the patient due to its participation in the study.
  5. A vascular risk, metabolic, infectious, neoplastic renal or as follows:

    • Patient at high cardiovascular risk: heart disease or vascular history of proven, type 2 diabetes at high cardiovascular risk *, vascular risk> 20% at 10 years (Framingham equation) Dyslipidemia • severe uncontrolled lipid-lowering therapy

    • Active Liver disease and liver failure
    • Neutropenia (<1500 / mm3) at the time of the introduction of Kineret / Placebo; and a patient with initial neutropenia may be included in the study if it corrects under Cortancyl®, and that the experimental treatment (Anakinra-Kineret / PLACEBO) may be commenced within 15 days after prednisone.

    Neoplasia under 5 years except carcinoma in situ of the cervix and skin cancer (excluding melanoma) with complete excision whose boundaries pass in safe area.

    • Severe renal impairment (clearance <30mL / min)

    * The high cardiovascular risk patients with diabetes are defined by:

    - A kidney disorder (proteinuria> 300mg / 24h or creatinine clearance <60mL / min according to Cockroft)

    - Or at least two of the following risk factors:

    - Men over 50 years, over 60 year old woman

    • History of premature coronary disease: myocardial infarction or sudden death in the father or relative in the first degree male before age 55 and before age 65 for females
    • Current or quit smoking for less than 3 years
    • High blood pressure treated or not
    • HDL cholesterol <0.40 g / L regardless of sex
    • Microalbuminuria (> 30 mg / 24h) NB: The moderate renal impairment (clearance ≥ 30 mL / min and <50 mL / min) is not here a criterion for non-inclusion, but the appropriate injection KINERET (anakinra) provided daily will be made every two days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02902731

Layout table for location contacts
Contact: Achille AOUBA, MD PHD +33231064579 aouba-a@chu-caen.fr
Contact: Francois FOURNEL, MD +33231065488 fournel-f@chu-caen.fr

Layout table for location information
Pr Aouba Recruiting
Caen, France, 14000
Sponsors and Collaborators
University Hospital, Caen
Hôpital Claude-Huriez
Amiens University Hospital
University Hospital, Rouen
University Hospital, Limoges
Central Hospital Saint Quentin
Valenciennes Hospital, Valenciennes, FRANCE
Layout table for investigator information
Principal Investigator: Achille AOUBA, MD PHD CHU CAEN
Layout table for additonal information
Responsible Party: University Hospital, Caen
ClinicalTrials.gov Identifier: NCT02902731    
Other Study ID Numbers: 2015-005804-27 N° CHU : 15-200
First Posted: September 16, 2016    Key Record Dates
Last Update Posted: February 25, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: It will be planify

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Polymyalgia Rheumatica
Giant Cell Arteritis
Vascular Diseases
Cardiovascular Diseases
Vasculitis, Central Nervous System
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Skin Diseases, Vascular
Skin Diseases
Autoimmune Diseases
Immune System Diseases
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents